As ER and PR status are routinely assessed in all newly diagnosed invasive breast tumours and in breast cancer recurrences, as well as their expression being the most important predictive marker for prognosis and response to endocrine therapy, these findings have critical implications for decisions made regarding diagnosis, prognosis and/or treatment options in breast cancer patients. Here, PGR is linked to breast carcinoma.